Hematological events and thyroid status in Imatinib treated CML Iraqi

J. Khaleel, Khaleed

	Hematological events and thyroid status in Imatinib treated CML Iraqi
Iraqi Journal of Cancer and Medical Genetics
Article 1, Volume 9, Issue 2, 2016, Pages 133-137
Author
Khaleed J. Khaleel
Abstract
Background: Chronic myeloid leukemia (CML) is myeloproliferative of hematopoietic stem cells resulting in marked in- creased in granulocytes, platelets and red cells. Imatinib mesylate (IM) is potent tyrosine kinase inhibitor acts by occupying ATP binding site for BCR-ABL oncoprotein pre- venting phosphorylation of substrate and interrupting contact with protein. Aim of study: Evaluation of thyroid function and myelosuppresion induced by IM in CML patients. Materials and Methods: The study enrolled 13 patients with CML treated by IM for more than 6 months. Total blood count and blood lm and thyroid function. Tests (T1 ,T4 and TSH) were performed. Results: All patients belong to Grade3 and Grade2 only of mylosuppresion, the most common cytopenia is neutropenia in (7) patients, anemia in (5) patients and only (4)patients having thrombocytopenia. Only three patients don’t achieve remission (6.6 %).Regarding thyroid function only one patient has high TSH level with normal T1 and T4. In spite of TSH level in patients signi cantly higher than the control group the mean values of two group were within normal range. Non-signi cant difference in T1 and T4 between the control and patients groups. Conclusion: IM do not seem to has clinically signi cant effect on thyroid function. However, thyroid function test is indicated before initiated of treatment with IM. Also CBC is highly recommended for monitoring CML patients on IM.
Keywords
CML; Thyroid function; Imatinib

Statistics Article View: 96 PDF Download: 66